Please find below some information regarding the timelines for the EU Commission study on pharmaceutical incentives as well as upcoming institutional meetings and events, which you may find interesting to attend.
1. study on pharmaceutical incentives – expected timelines
In late 2016, it was suggested by a Commission representative, that the much-awaited study on the economic impact of supplementary protection certificates (SPCs), pharmaceutical incentives and rewards in Europe, would likely be published sometimes in 2018.
It is now estimated that the timelines are as follows, according to an understanding of the call for tenders the EU Commission published in December 2016:
- Q3 2017: Start of the study, expected to run for 9 months, by the winning contractor,
- Late Q2 2018: findings of the study on pharmaceutical incentives, SPCs and rewards unveiled.
2. Upcoming Brussels-based and EU institutional meetings and events
In particular, we would like to draw your attention to the below events and meetings:
- EMA 10th Industry Platform Meeting on the operation of EU pharmacovigilance, which will take place at the European Medicines Agency on 3 February 2017, at 10:00-13:30 UK time.
- “Inside the Minds of Regulators: Perspectives on EU pharmaceutical and medical devices law”, co-organised by Sidley, Navitas, Pwc and EUCOPE, on 9 February 2017, at THE Hotel Brussels (Belgium). Representatives from DG GROW (S. D’Acunto, Head of Unit), DG SANTE (A. Rys, Director) and DG COMP (P. Csiszar, Director) as well as from the industry will discuss for a day the impacts of new pharmaceutical and medical devices legislation and regulation, and the competition law issues affecting the pharmaceutical sector. You can find more information and contact for registration here.
- EURORDIS’ “2nd Multi-Stakeholder Symposium on Improving Patient Access to Rare Disease Therapies”, taking place on 22/23 February 2017, in Hotel Le Plaza, Brussels (Belgium). The two-day event aims to bring together patient advocates, payers, HTA bodies, academics, clinicians, policy makers, investors and industry representatives, and to discuss interests and challenges in improving patients’ access to rare disease therapies. The agenda can be accessed here, and registrations filled in here.